Zandra Klippel

Carfilzomib, dexamethasone, and daratumumab versus carfilzomib and dexamethasone for patients with relapsed or refractory multiple myeloma (CANDOR): results from a randomised, multicentre, open-label, phase 3 study

Meletios Α. Dimopoulos, Hang Quach, María‐Victoria Mateos et al. · The Lancet · 2020 · 422 citations

Medicine, Pharmacology, Pharmacotherapy +14

Isatuximab, Bortezomib, Lenalidomide, and Dexamethasone for Multiple Myeloma

Thierry Façon, Meletios Α. Dimopoulos, Xavier P Leleu et al. · New England Journal of Medicine · 2024 · 243 citations

Pharmacy, Hematology, Pharmacotherapy +16

Carfilzomib or bortezomib with melphalan-prednisone for transplant-ineligible patients with newly diagnosed multiple myeloma

Thierry Façon, Jae Hoon Lee, Philippe Moreau et al. · Blood · 2019 · 130 citations · Full text

Medicine, Hematology, Pharmacotherapy +14

Relationship between severity and duration of chemotherapy-induced neutropenia and risk of infection among patients with nonmyeloid malignancies

Yanli Li, Zandra Klippel, Xiaolong Shih et al. · Supportive Care in Cancer · 2016 · 48 citations

Medicine, Hematology, Oncology +14

Carfilzomib, Dexamethasone, and Daratumumab Versus Carfilzomib and Dexamethasone for the Treatment of Patients with Relapsed or Refractory Multiple Myeloma (RRMM): Primary Analysis Results from the Randomized, Open-Label, Phase 3 Study Candor (NCT03158688)

Saad Z. Usmani, Hang Quach, María‐Victoria Mateos et al. · Blood · 2019 · 43 citations

Medicine, Pharmacology, Pharmacotherapy +17